Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Turing's Shkreli Caves To Pressure; Lowering Daraprim Price

This article was originally published in Scrip

Executive Summary

Martin Shkreli, the hedge funder-turned-pharma CEO, who jacked up the price of a rare disease medicine from $13.50 to $750 per pill after acquiring it last month, found out the hard way that picking a fight with the HIV/AIDS advocacy community and presidential candidates already on the war path about skyrocketing drug prices wasn't the best idea.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel